Deloitte Legal congratulates Aphea.Bio on winning the M&A Award “Best Venture Capital Deal – Life Sciences 2023” with regard to their Series C financing
Taking on your challenges
27 November 2023
The jury was impressed by Aphea.Bio. Started in 2017 as a spin-off of VIB, the cradle of many successful biotech companies, Aphea.Bio turned in six years’ time into a top-notch agricultural technology company. In the summer of 2023, the company secured a 70 million euro Series C funding round provided by highly reputable international and local investors and supported by the Bill & Melinda Gates Foundation.
The jury was charmed by the combination of a world-class team under the inspired leadership of co-founder and CEO Isabel Vercauteren, with strong scientific foundations and promising products that can effectively tackle the significant challenges faced in modern agricultural practices. Aphea.Bio’s ultimate goal is to supply the growing world population, both in North and South, with sufficient and healthy food.